| Oct 4 |
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
|
| Oct 3 |
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
|
| Sep 27 |
Telix Pharmaceuticals (ASX:TLX) Boosts Growth with Cardinal Health Alliance and New FDA Submissions
|
| Sep 22 |
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
|
| Sep 17 |
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
|
| Sep 10 |
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
|
| Sep 3 |
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
|
| Aug 27 |
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
|
| Aug 26 |
Telix Announces Reorganisation to Deliver on Strategic Priorities
|
| Aug 22 |
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
|
